Dyne Therapeutics Inc experienced a significant price drop of 16.89%, crossing below its 5-day SMA amid the announcement of a $300 million underwritten public offering.
The offering, which includes an additional $45 million option for underwriters, is aimed at enhancing the company's financial flexibility to support its research and development efforts. Major investment banks such as Morgan Stanley and Jefferies are involved in the underwriting process, which may bolster investor confidence despite the current market conditions.
This public offering is expected to provide necessary funding for Dyne's clinical programs targeting genetically driven neuromuscular diseases. However, the market's reaction indicates caution among investors, reflecting uncertainties surrounding the offering's completion and its potential impact on the company's stock performance.
Wall Street analysts forecast DYN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DYN is 38.40 USD with a low forecast of 17.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast DYN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DYN is 38.40 USD with a low forecast of 17.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 17.700
Low
17.00
Averages
38.40
High
60.00
Current: 17.700
Low
17.00
Averages
38.40
High
60.00
Jefferies
Ramoun Lazar
Hold -> Buy
upgrade
$4
2026-01-20
Reason
Jefferies
Ramoun Lazar
Price Target
$4
AI Analysis
2026-01-20
upgrade
Hold -> Buy
Reason
Jefferies analyst Ramoun Lazar upgraded Dyno Nobel to Buy from Hold with a A$4 price target. The firm sees scope for a re-rating as Dyno continues to deliver self-help led growth and exits volatile fertilizers by the end of FY26, the analyst tells investors.
Evercore ISI
Gavin Clark-Gartner
Outperform
downgrade
$38 -> $36
2025-12-15
Reason
Evercore ISI
Gavin Clark-Gartner
Price Target
$38 -> $36
2025-12-15
downgrade
Outperform
Reason
Evercore ISI analyst Gavin Clark-Gartner lowered the firm's price target on Dyne Therapeutics to $36 from $38 and keeps an Outperform rating on the shares. Efficacy and safety metrics are meeting expectations with positive trends on functionality, which is "encouraging" following the company's recent fundraising, the analyst tells investors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DYN
Unlock Now
Stifel
NULL -> Buy
maintain
$36 -> $39
2025-12-11
Reason
Stifel
Price Target
$36 -> $39
2025-12-11
maintain
NULL -> Buy
Reason
Stifel raised the firm's price target on Dyne Therapeutics to $39 from $36 and keeps a Buy rating on the shares. The firm "refreshed diligence" on many companies within its biotechnology coverage universe and made a number of model, estimate and price target changes in a 2026 look ahead note for the group.
Oppenheimer
Kostas Biliouris
Perform
to
Outperform
upgrade
$11 -> $40
2025-12-10
Reason
Oppenheimer
Kostas Biliouris
Price Target
$11 -> $40
2025-12-10
upgrade
Perform
to
Outperform
Reason
As previously reported, Oppenheimer analyst Kostas Biliouris upgraded Dyne Therapeutics to Outperform from Perform with a price target of $40, up from $11. The firm notes Dyne has been trading at a discount compared to closest competitor Avidity, mainly due to investor concerns around the myotonic dystrophy type 1 program's timeline, Phase III powering, and accelerated approval possibility. Although appreciating investor concerns around DM1, Oppenheimer believes that the biggest catalyst for Dyne moving forward is the read-through from competitor Avidity's Phase III readout in the second half of 2026, expected to be positive and with the potential to drive upside of about 50%-plus in the stock. Recall, Avidity's recent acquisition news drove more than 40% upside in Dyne.
About DYN
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
